keyword
https://read.qxmd.com/read/38623612/robot-assisted-distal-gastrectomy-and-local-resection-for-gastric-cancer-and-gastrointestinal-stromal-tumor
#1
Chihiro Ishizuka, Takahisa Ishikawa, Hayato Yagi, Yoichi Yamamoto, Daisuke Koro, Takahiro Nishikoshi, Yasuyuki Koshizuka, Naoyuki Yanagida, Taiichiro Shibaki, Hiromitsu Akabane, Shunsuke Yasuda, Kei Ishibashi, Akinobu Taketomi
Gastrointestinal stromal tumors surrounding the esophagogastric junction are often challenging to resect, with no consensus regarding the optimal surgical technique. Here in, we present a case of concurrent gastric cancer in the antrum and gastrointestinal stromal tumors adjacent to the esophagogastric junction. The patient underwent simultaneous distal gastrectomy and local resection assisted by a surgical robot, avoiding the need for total gastrectomy. The utilization of robot-assisted surgery has become an increasingly popular technique, holding promise for simplifying complex surgical procedures across diverse medical settings...
July 2024: Asian Journal of Endoscopic Surgery
https://read.qxmd.com/read/38618997/the-advent-of-the-first-electric-driven-eus-guided-17-gauge-core-needle-biopsy-a-pilot-study-on-subepithelial-lesions
#2
JOURNAL ARTICLE
Fredrik Swahn, Robert Glavas, Lucin Hultin, Malin Wickbom
BACKGROUND AND AIMS: This pilot study aimed to evaluate safety and tissue sampling from subepithelial lesions (SEL) in the upper gastrointestinal tract with a novel electric motor driven endoscopic ultrasonography (EUS)-guided 17-gauge (G) size core needle biopsy (CNB) instrument. METHODS: An investigator-led prospective open label, performance and safety control study, including seven patients (female n  = 4, median 71 y, range 28-75) with a determined SEL (median size 30 mm, range 17-150 mm) in the upper digestive tract (stomach n  = 6, duodenum n  = 1) were eligible and later followed up 14 days after index procedure...
April 15, 2024: Scandinavian Journal of Gastroenterology
https://read.qxmd.com/read/38614267/potential-therapeutic-targets-in-myeloid-cell-therapy-for-overcoming-chemoresistance-and-immune-suppression-in-gastrointestinal-tumors
#3
REVIEW
Jiawei Fan, Jianshu Zhu, He Zhu, Hong Xu
In the tumor microenvironment (TME), myeloid cells play a pivotal role. Myeloid-derived immunosuppressive cells, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), are central components in shaping the immunosuppressive milieu of the tumor. Within the TME, a majority of TAMs assume an M2 phenotype, characterized by their pro-tumoral activity. These cells promote tumor cell growth, angiogenesis, invasion, and migration. In contrast, M1 macrophages, under appropriate activation conditions, exhibit cytotoxic capabilities against cancer cells...
April 11, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/38609732/english-version-of-japanese-clinical-practice-guidelines-2022-for-gastrointestinal-stromal-tumor-gist-issued-by-the-japan-society-of-clinical-oncology
#4
JOURNAL ARTICLE
Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Takahashi, Hironobu Hashimoto, Midori Udo, Minako Araki, Sumito Nishidate
The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients' wishes, medical economic perspective, etc...
April 13, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38609414/comparable-long%C3%A2-term-survival-outcomes-of-endoscopic-treatment-versus-surgical-treatment-for-gastrointestinal-stromal-tumors-with-a-diameter-of-5-10%C3%A2-cm
#5
JOURNAL ARTICLE
Zide Liu, Qing Tao, Yonghui Wu, Chunyan Zeng, Youxiang Chen
Currently, endoscopic treatment for small gastrointestinal stromal tumors (GIST) has been widely accepted. However, for tumors larger than 5 cm, endoscopic treatment has not been recognized by national guidelines as the standard therapy due to concerns about safety and adverse tumor outcomes. Therefore, this study compares the long-term survival outcomes of endoscopic treatment and surgical treatment for GIST in the range of 5-10 cm. We selected patients with GIST from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015...
April 12, 2024: Scientific Reports
https://read.qxmd.com/read/38607211/diagnostic-value-of-transabdominal-ultrasonography-in-gastrointestinal-malignant-tumors
#6
JOURNAL ARTICLE
Jing-Yun Dong, Yan-Bing Gao, Li-Wei Tang, Jing Zheng
OBJECTIVE: To explore the application value of transabdominal ultrasonography in the diagnosis of gastrointestinal malignant tumors. METHODS: This study retrospectively analyzed the transabdominal ultrasound imaging data of 284 patients with gastrointestinal tumors admitted to our hospital from April 2019 to March 2022 and assessed the accuracy of transabdominal ultrasound in diagnosing different types of gastrointestinal tumor diseases. The diagnostic accuracy of transabdominal ultrasonography for TNM staging of gastrointestinal malignancies was calculated...
April 12, 2024: Alternative Therapies in Health and Medicine
https://read.qxmd.com/read/38594390/financial-difficulties-experienced-by-patients-with-gastrointestinal-stromal-tumours-gist-in-the-netherlands-data-from-a-cross-sectional-multicentre-study
#7
MULTICENTER STUDY
Deborah van de Wal, Dide den Hollander, Ingrid M E Desar, Hans Gelderblom, Astrid W Oosten, Anna K L Reyners, Neeltje Steeghs, Olga Husson, Winette T A van der Graaf
PURPOSE: This study aims to (1) explore the prevalence of patient-reported financial difficulties among GIST patients, differentiating between those currently undergoing tyrosine kinase inhibitor (TKI) treatment and those who are not; (2) investigate associations between financial difficulties and sociodemographic and clinical characteristics, work, cancer-related concerns, anxiety and depression and (3) study the impact of financial difficulties on health-related quality of life. METHODS: A cross-sectional study was conducted among Dutch GIST patients diagnosed between 2008 and 2018, who were invited to complete a one-time survey between September 2020 and June 2021...
April 10, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38587549/-gastrointestinal-stromal-tumors-where-do-we-stand
#8
JOURNAL ARTICLE
Eva Wardelmann, Anna Kuntze, Artem Voloshin, Sandra Elges, Marcel Trautmann, Wolfgang Hartmann
For more than 20 years gastrointestinal stromal tumors (GIST) have been a paradigm for a targeted treatment with tyrosine kinase inhibitors. A fundamental prerequisite for a neoadjuvant or adjuvant treatment of localized GIST or an additive treatment of metastatic GIST is the molecular typing of tumors, ideally at the initial diagnosis. In addition, the possibility of a hereditary or syndromic predisposition must be considered because this results in consequences for the treatment and a different follow-up strategy...
April 8, 2024: Pathologie (Heidelb)
https://read.qxmd.com/read/38586745/the-role-of-neoadjuvant-therapy-in-a-giant-gastric-gastrointestinal-stromal-tumour-a-case-report-and-review-of-the-literature
#9
Jolan S Alsaud, Saja Alruqayi, Abdulaziz Alomair
Gastric gastrointestinal stromal tumour (GIST) is a rare disease with an annual incidence of 10 cases per million. Herein, we present the case of a 45-year-old man who visited our clinic with complaints of weight loss and anorexia, without changes in bowel habits or vomiting, for four months. On physical examination, all vital signs were normal. The abdomen was distended without tenderness and had a giant upper abdominal mass. Tumour marker investigation revealed high levels of cancer antigen 125 with normal levels of alpha-1-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen...
March 2024: Curēus
https://read.qxmd.com/read/38576236/clinically-undiagnosed-diseases-in-autopsies-frequency-and-risk-factors
#10
JOURNAL ARTICLE
Umberto Maccio, Christoph Andreas Meier, Michael Reinehr, Frank Ruschitzka, Reto Schüpbach, Holger Moch, Zsuzsanna Varga
CONTEXT.—: Autopsies can reveal clinically undiagnosed diseases. However, the frequency of first diagnoses at autopsy and their association with clinically known risk factors are not well understood because of lack of systematic analyses addressing this topic. OBJECTIVE.—: To perform a large retrospective cohort analysis on the frequency of clinically undiagnosed postmortem findings and correlate these with patients' risk factors. DESIGN...
April 5, 2024: Archives of Pathology & Laboratory Medicine
https://read.qxmd.com/read/38572434/mitochondrial-energy-metabolism-related-gene-signature-as-a-prognostic-indicator-for-pancreatic-adenocarcinoma
#11
JOURNAL ARTICLE
Yu Ma, Ronghao Tang, Peilin Huang, Danhua Li, Meijian Liao, Shoucui Gao
Background: Pancreatic adenocarcinoma (PAAD) is a highly malignant gastrointestinal tumor and is associated with an unfavorable prognosis worldwide. Considering the effect of mitochondrial metabolism on the prognosis of pancreatic cancer has rarely been investigated, we aimed to establish prognostic gene markers associated with mitochondrial energy metabolism for the prediction of survival probability in patients with PAAD. Methods: Gene expression data were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases, and the mitochondrial energy metabolism-related genes were obtained from the GeneCards database...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38568688/treatment-access-for-gastrointestinal-stromal-tumor-in-predominantly-low-and-middle-income-countries
#12
JOURNAL ARTICLE
Edward Lloyd Briercheck, J Michael Wrigglesworth, Ines Garcia-Gonzalez, Catherina Scheepers, Mei Ching Ong, Viji Venkatesh, Philip Stevenson, Alicia A Annamalay, David G Coffey, Aparna B Anderson, Pat Garcia-Gonzalez, Michael J Wagner
IMPORTANCE: Gastrointestinal stromal tumor (GIST) is a rare cancer treated with the tyrosine kinase inhibitors imatinib mesylate or sunitinib malate. In general, in low- and middle-income countries (LMICs), access to these treatments is limited. OBJECTIVE: To describe the demographic characteristics, treatment duration, and survival of patients with GIST in LMICs treated with imatinib and sunitinib through The Max Foundation programs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective database cohort analysis included patients in 2 access programs administered by The Max Foundation: the Glivec International Patient Assistance Program (GIPAP), from January 1, 2001, to December 31, 2016, and the Max Access Solutions (MAS) program, January 1, 2017, to October 12, 2020...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38567336/a-new-green-fluorimetric-micelle-complexation-approach-for-reduction-of-the-consumed-solvent-and-quantification-of-avapritinib-in-biological-fluids
#13
JOURNAL ARTICLE
Baher I Salman, Hany A Batakoushy, Roshdy E Saraya, Mohamed A A Abdel-Aal, Adel Ehab Ibrahim, Yasser F Hassan, Ahmed I Hassan, Ehab A M El-Shoura
Avapritinib (AVA) is the first medication authorized by the US-FDA in 2020 for the management of gastrointestinal stromal tumours (GISTs) that can't be treated by surgery. Cancer is among the most common causes of death worldwide and is the second most common cause of death after cardiovascular disease. Therefore, a quick, easy, sensitive, and straightforward fluorimetric approach was used to analyse AVA in pharmaceutical materials and blood plasma (pharmacokinetic). The suggested technique relies on 2% sodium dodecyl sulphate (SDS, pH 4) micellar system augmentation of the fluorescence of the tested drug...
March 26, 2024: RSC Advances
https://read.qxmd.com/read/38531231/long-term-outcomes-of-endoscopic-therapy-versus-surgical-resection-for-2-5%C3%A2-cm-gastric-gastrointestinal-stromal-tumors-a-population-based-comparative-study
#14
JOURNAL ARTICLE
Yixia Chai, Bitao Lin, Jun Zhong, Xiaosheng Wu, Xin Lin, Xiaoyue Ge, Jiayi Jiang, Zhenye Liang, Side Liu, Chuncai Gu
BACKGROUND: Endoscopic therapy (ET) of gastrointestinal stromal tumors (GIST) has become a viable treatment. We intended to compare long-term outcomes of ET versus surgical resection for 2-5 cm GIST using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: A multicenter retrospective study was conducted to compare the long-term outcomes of patients treated with ET and surgical resection for GIST. The multivariate Cox proportional hazards models were used to identify predictors for patients survival...
March 15, 2024: European Journal of Surgical Oncology
https://read.qxmd.com/read/38516246/immune-signature-of-small-bowel-adenocarcinoma-and-the-role-of-tumor-microenvironment
#15
EDITORIAL
Grigorios Christodoulidis, Marina Nektaria Kouliou, Konstantinos Eleftherios Koumarelas
In this editorial we comment on the article published "Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment". Small bowel adenocarcinoma (SBA) is a rare gastrointestinal neoplasm and despite the small intestine's significant surface area, SBA accounts for less than 3% of such tumors. Early detection is challenging and the reason arises from its asymptomatic nature, often leading to late-stage discovery and poor prognosis. Treatment involves platinum-based chemotherapy with a 5-fluorouracil combination, but the lack of effective chemotherapy contributes to a generally poor prognosis...
February 28, 2024: World Journal of Gastroenterology: WJG
https://read.qxmd.com/read/38514970/acidity-triggered-sticky-spotlight-cck2r-targeted-tme-sensitive-nir-fluorescent-probes-for-tumor-imaging-in-vivo
#16
JOURNAL ARTICLE
Ruiqi Sun, Yuxin Wang, Wenhui Shi, Hongfu Zhang, Jianhua Liu, Weina He
Cancer which causes high mortality globally threatens public health seriously. There is an urgent need to develop tumor-specific near-infrared (NIR) imaging agents to achieve precise diagnosis and guide effective treatment. In recent years, imaging probes that respond to acidic environments such as endosomes, lysosomes, or acidic tumor microenvironments (TMEs) are being developed. However, because of their nonspecific internalization by both normal and tumor cells, resulting in a poor signal-to-noise ratio in diagnosis, these pH-sensitive probes fail to be applied to in vivo tumor imaging...
March 21, 2024: Bioconjugate Chemistry
https://read.qxmd.com/read/38509504/transgelin-2-a-novel-cancer-stem-cell-related-biomarker-is-a-diagnostic-and-therapeutic-target-for-biliary-tract-cancer
#17
JOURNAL ARTICLE
Jung Hyun Jo, Soo Been Park, Joowon Chung, Taeyun Oh, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Dawoon E Jung, Si Young Song
BACKGROUND: Biliary tract cancer (BTC) is a relatively rare but aggressive gastrointestinal cancer with a high mortality rate. Cancer stem cell (CSC) populations play crucial roles in tumor biology and are responsible for the low response to anti-cancer treatment and the high recurrence rate. This study investigated the role of Transgelin-2 (TAGLN2), overexpressed in CSC in BTC cells, and analyzed its expression in patient tissues and serum to identify potential new targets for BTC. METHODS: TAGLN2 expression was suppressed by small-interfering or short hairpin RNAs, and its effects on tumor biology were assessed in several BTC cell lines...
March 20, 2024: BMC Cancer
https://read.qxmd.com/read/38506384/emergent-approach-to-small-bowel-tumors-diagnosis-and-treatment
#18
JOURNAL ARTICLE
Enes Sahin, Kazım Şahin, Haşim Köken, Sertaç Ata Güler, Turgay Şimşek, Nihat Zafer Utkan, Mustafa Şahin
BACKGROUND: This study presents the diagnosis and treatment of rare small bowel tumors through clinical cases. METHODS: Patients treated between 2000 and 2023 were included in the study. The clinical records of the patients were analyzed retrospectively. RESULTS: A total of 34 patients were included in the study. Of these patients, 26 (75.5%) were male and eight (23.5%) were female. The mean age of the patients was 62.1 years. The most common symptoms and signs were abdominal pain (76...
March 2024: Turkish Journal of Trauma & Emergency Surgery: TJTES
https://read.qxmd.com/read/38504089/the-development-of-a-prediction-model-based-on-deep-learning-for-prognosis-prediction-of-gastrointestinal-stromal-tumor-a-seer-based-study
#19
JOURNAL ARTICLE
Junjie Zeng, Kai Li, Fengyu Cao, Yongbin Zheng
Accurately predicting the prognosis of Gastrointestinal stromal tumor (GIST) patients is an important task. The goal of this study was to create and assess models for GIST patients' survival patients using the Surveillance, Epidemiology, and End Results Program (SEER) database based on the three different deep learning models. Four thousand five hundred thirty-eight patients were enrolled in this study and divided into training and test cohorts with a 7:3 ratio; the training cohort was used to develop three different models, including Cox regression, RSF, and DeepSurv model...
March 19, 2024: Scientific Reports
https://read.qxmd.com/read/38487849/pancdr-precise-medicine-prediction-using-an-adversarial-network-for-cancer-drug-response
#20
JOURNAL ARTICLE
Juyeon Kim, Sung-Hye Park, Hyunju Lee
Pharmacogenomics aims to provide personalized therapy to patients based on their genetic variability. However, accurate prediction of cancer drug response (CDR) is challenging due to genetic heterogeneity. Since clinical data are limited, most studies predicting drug response use preclinical data to train models. However, such models might not be generalizable to external clinical data due to differences between the preclinical and clinical datasets. In this study, a Precision Medicine Prediction using an Adversarial Network for Cancer Drug Response (PANCDR) model is proposed...
January 22, 2024: Briefings in Bioinformatics
keyword
keyword
74071
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.